Sullivan et al. Vasculitis in VEXAS. 81 patients. 27% vasculitis. Cutaneous SVV 20%, AAV 2.5%, cutaneous MVV 2.5%, LVV 2.5%. @RheumNow #ACR24 Abstr#2651 https://t.co/AV3RcuSKpV https://t.co/xrax025TzP

• Vasculitis Associated with VEXAS Syndrome - ACR Meeting Abstracts
• https://x.com/RichardPAConway/status/1858619438720757790/photo/1

How often do you ask about #fatigue, #depression & #anxiety in pts with RMDs? Study of >1000 pts found anxiety symptoms in 1/3 pts and significant association between fatigue & anxiety and depression Highlights importance of regular review of MH symptoms Ab2657 #ACR24 @RheumNow https://t.co/0zMOMybrCI

• https://x.com/DrMiniDey/status/1858620697188462887/photo/1

A#2652 NEWTON study 🇫🇷 Retrosp cohort 51% relapse. Median @8.7 mos, dose 9mg pred Rf: limb art involv- HR 1.9 Pred taper speed not risk for relapse Most relapse -> incr GCs Toci 1/3 at dx, 50% stopped -61% d/c due to remission, 39% SEs -1/3 relapse after d/c @RheumNow #ACR24 https://t.co/NP0wieDmvo

• https://x.com/ericdeinmd/status/1858620704528146555/photo/1

Peyrac et al. 211 GCA. Relapse in 52% at median 261 days (so 1st year). 83% on GCs at relapse, median dose 6.5mg pred. 36% relapse post-toc discontinuation, at median 133 days. 64% no relapse when toc stopped, at median 511 days @RheumNow #ACR24 Abstr#2652 https://t.co/NqtdDNGGoc https://t.co/mXD8x7O6Ww

• You searched for Characteristics of Relapse and Therapeutic Management in Giant…
• https://x.com/RichardPAConway/status/1858621703745925264/photo/1

What is the effect of cs/bDMARDs on weight in #PsA? ⬇️Weight loss seen with: IL17i IL23i csDMARDs ⬆️Weight gain seen with: TNFi IL12/23i Important to consider #comorbidity & #BMI in management decisions in PsA Ab2639 #ACR24 @RheumNow

A New ACR Dr. Jack Cush highlights a few notable changes to the ACR meeting format this year, and offers pointers on the best way to stay informed and abreast of reporting from the #ACR24 Convergence meeting in Washington, DC. https://t.co/YmI6s1TanV https://t.co/hsByGEBtnz

• A New ACR | RheumNow

A#2648 PET for GCA Delayed imaging at 180 min improve dx performance for pts on GCs Optimal PET w/in 3 days of GC, most patients unable to do w/in that window Delay has sensitivity 92% even on prednisone - may be good tool for pts unable to get early PET/CT #ACR24 @RheumNow https://t.co/kxpNfRqkGN

• https://x.com/ericdeinmd/status/1858606871726395589/photo/1
• https://x.com/ericdeinmd/status/1858606871726395589/photo/1
• https://x.com/ericdeinmd/status/1858606871726395589/photo/1

Study by Maria Dall'Era et al. compared voclosporin-based triple immunosuppressive therapy with high-dose GC in active lupus nephritis. - Fewer adverse events in the voclosporin group, despite a higher incidence of specific issues like decreased GFR and hypertension. - 25%… https://t.co/ToRu2rdErC https://t.co/uUXzNNuLDb

• https://x.com/i/web/status/1858608171926814731
• https://x.com/synovialjoints/status/1858608171926814731/photo/1

@YooJinKimYJK @andreafava et al: 20% of pts in their #lupus cohort had recurrent pericarditis. Majority had 1 recurrence (51%) Independent predictors of recurrence: Younger age Prednisone tx Active dse Time from initial episode 🔅regular ffup is 🔑 @RheumNow #ACR24 abs2372 https://t.co/UELwE31X0u

• https://x.com/RHEUMarampa/status/1858608830856179904/photo/1

➡️More DMARD-exposed pts w late-onset RA reduce long-term GC use than DMARD-unexposed ➡️Persistent GC use is common ➡️In DMARD-exposed, GC use may be related to limited access to high-cost drugs ➡️In DMARD-unexposed, comorbidity burden may limit DMARD use Ab2606 #ACR24 @RheumNow

How do you manage DMARDs when giving the recombinant #zoster #vaccine (#RZV)? ➡️75 pts with ARDs 💉2-week #MTX discontinuation after each dose of RZV ⏩Significant boost in immune response without difference in flare rates Ab2612 #ACR24 @RheumNow https://t.co/o4iqj3e1Be

• https://x.com/DrMiniDey/status/1858609875758010555/photo/1

A#2649 Relapsing Polychondritis Latent Class Analysis to define clinical phenotypes of heterogeneous dx Type 1- ear, nose, subglottic stenosis 2- tracheo/bronchomalacia 3- absence tracheomalacia Decision tree to classify pts in subgroups #ACR24 @RheumNow https://t.co/xpZedPVl7f

• https://x.com/ericdeinmd/status/1858609912286191654/photo/1
• https://x.com/ericdeinmd/status/1858609912286191654/photo/1
• https://x.com/ericdeinmd/status/1858609912286191654/photo/1
• https://x.com/ericdeinmd/status/1858609912286191654/photo/1

Loiseau et al. 4700 pSS, 47000 comparators. pSS associated with increased risk of every CV/VTE outcome. Did not have that in my priors! @RheumNow #ACR24 Abstr#2631 https://t.co/QKemUhbcG8 https://t.co/twpjdS2L63

• Risk of Atherosclerotic Cardiovascular Events and Venous Thromboembolism in Peo…
• https://x.com/RichardPAConway/status/1858611134086987820/photo/1

A#2650 MRI can show extent of vessel wall inflamm to guide severity of GCA Brain & orbital MRI performed Assessed 7 arteries bilaterally -> CAMRIS-GCA MRI score (0-10) 33 GCA (17 ocular), 41 not GCA CAMRIS-GCA ass w/ ocular GCA, higher severity. Improved w Rx @RheumNow #ACR24 https://t.co/19XCuZJXqF

• https://x.com/ericdeinmd/status/1858613190541631668/photo/1
• https://x.com/ericdeinmd/status/1858613190541631668/photo/1
• https://x.com/ericdeinmd/status/1858613190541631668/photo/1